

now being developed for tetanus, diphtheria, AIDS, and many other diseases. Promising data has been obtained. The potential advantages of such controlled release vaccines include improved patient compliance (particularly in the developing world, where patients frequently do not return for repeat injections) and potential higher antibody titers. New routes of entry for polymer-based vaccines are also being considered. Such routes include mucosal (such as oral and nasal)<sup>7</sup> and parenteral (such as subcutaneous and intramuscular)<sup>6</sup>. The paper by Sherwood et al is important for a number of reasons. First, it offers a novel portal of entry—vaginal—

which may be useful for the delivery of a number of agents and vaccines. Second, it provides a potential new approach for treating genital herpes and other STD pathogens. It is an important study that should have significant future implications.

1. Sherwood, J.K. et al. 1996. *Nature Biotechnology* **14**:468-471.
2. Langer, R. and Vacanti, J.P. 1993. *Science* **260**:920-926.
3. Lanza, R.P. and Chick, W.L. 1995. *Scientific American Science & Medicine* **2**:16-25.
4. Langer, R. and Folkman, J. 1976. *Nature* **263**:797-800.
5. Preis, I. and Langer, R. 1979. *J. Immunol. Methods* **28**:193-197.
6. Morris, W. et al. 1994. *Vaccine* **12**:5-11.
7. Eldridge, J.H. et al. 1991. *Infect. Immun.* **59**:2978-2986.

## Tissue-specific gene therapy

Mima Predich

Peptide-displaying bacteriophage could emerge as vectors for gene therapy, suggests a recent report in the March 1996 issue of *Nature Medicine* (2:299-305). A group from the University of Texas Southwestern Medical Center (Dallas, TX) describes peptide-displaying phages that have been selected to bind to specific tissues, that peptides may be useful in targeting gene therapy vectors to the cell type of interest. Clinical studies, however, are at least a few years away. "We have a long way to go, but the initial results are very positive, and tissue-specificity is likely to remain one of the key issues in gene therapy," comments principal author Stephen Johnston. Although this method will undoubtedly prove useful, selection of tissue-specific phage was performed in cell culture which, although the phage was cross-tested against other cell types, does not account for all the potential nonspecific binding in vivo. In vivo selection of phage may solve this problem (see "In vivo veritas: Live phage display panning," p.429).

Another recent study at Oregon Health Sciences University (Portland, OR), reported in *Nature Genetics* (12:266-273, March 1996), demonstrates successful correction of a lethal liver gene defect by direct injection of a retrovirus carrying the normal gene into the hepatic portal vein of affected mice or by transplantation of liver cells from wildtype, congenic animals. In both cases, hepatic cells expressing the gene have a selective growth advantage over the mutant cells, resulting in the repopulation of the liver with healthy hepatocytes. Since the selection of corrected liver cells overcomes the low transfer efficiency, a problem that has been responsible for the limited success of previous attempts at ex vivo liver gene therapy, this study is very encouraging. "Our work has implications for the gene therapy of several liver metabolic diseases, and we are hoping to extend our studies to affected humans," says Markus Grompe (Oregon Health Sciences University, Portland, OR), a lead investigator. "We are also very interested in the effect of corrected cells on the development of hepatocellular carcinoma, a frequent occurrence in humans and mice bearing a defect in the fumarylacetoacetate hydrolase (FAH) gene," says Grompe.

## CAN YOU RISK DELAYS SUBMITTING PROJECTS TO THE FDA?

LARK GUARANTEES 100% ACCURACY ON  
FDA SUBMISSION QUALITY DNA SEQUENCING.

**D**elays in submitting projects to the FDA cost companies time, money and competitive advantage in the market place.

### Lark FDA Submission Quality Sequencing

Lark specializes in handling FDA Submission Quality DNA Sequencing projects and can help you minimize costly delays.

### Lark Guarantee

Projects completed by Lark for FDA submission are guaranteed to be 100% accurate even in areas of high GC content or difficult secondary structure with 100% double stranded coverage of the sequenced region


### Lark Quality Control

All work performed at Lark is done in compliance with Good Laboratory Practices (GLPs) as published by the FDA.

READER INQUIRY NO. 234

### Lark Report

Results are presented in a comprehensive report that can be incorporated into an application to be submitted to the FDA.



Minimize the risk of delays on FDA Submission projects. Contact Lark for additional information or a quote on your next FDA Submission Quality DNA Sequencing project.

**Lark**  
TECHNOLOGIES  
INC.

USA: 9545 Katy Fwy, Ste. 465  
Houston, TX 77024-9870  
1-800-288-3720 or 713-464-7488,  
Fax: 713-464-7492

Email: [larksales@aol.com](mailto:larksales@aol.com)  
Europe: Tel: +44 (0) 1273-707500,  
Fax: +44 (0) 1273-707499.

Email: [Sequence@LarkDNA.CityScape.co.uk](mailto:Sequence@LarkDNA.CityScape.co.uk)